6/8/2010

GlaxoSmithKline submitted a marketing application to the European Medicines Agency for its lupus drug candidate Benlysta. The drugmaker, which co-develops Benlysta with Human Genome Sciences, also plans to file for FDA approval of the treatment later this month.

Full Story:
Reuters

Related Summaries